Morgan Stanley Landec Corp \Ca\ Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Landec Corp \Ca\ stock. As of the latest transaction made, Morgan Stanley holds 791,807 shares of LNDC stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

791,807

Previous 788,702 0.39%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	N/A	3,105 Added 0.39%	791,807 $0
Q4 2023 Feb 13, 2024	SELL	N/A	-6,239 Reduced 0.78%	788,702 $0
Q3 2023 Nov 15, 2023	SELL	N/A	-22,553 Reduced 2.76%	794,941 $0
Q2 2023 Aug 14, 2023	SELL	N/A	-51,606 Reduced 5.94%	817,494 $0
Q1 2023 May 15, 2023	BUY	N/A	229,501 Added 35.88%	869,100 $0

Q4 2022 Feb 14, 2023	BUY	$0.0 - $9.95 $0 - $244,391	24,562 Added 3.99%	639,599 $0
Q3 2022 Nov 14, 2022	BUY	$8.57 - $11.57 $53,528 - $72,266	6,246 Added 1.03%	615,037 $5.47 Million
Q2 2022 Oct 27, 2022	BUY	$8.84 - $11.64 $167,173 - $220,124	18,911 Added 3.21%	608,791 $6.07 Million
Q2 2022 Aug 15, 2022	BUY	$8.84 - $11.64 $167,173 - $220,124	18,911 Added 3.21%	608,791 $6.07 Million
Q1 2022 Oct 27, 2022	SELL	$10.07 - $11.93 $190,433 - $225,608	-18,911 Reduced 3.11%	589,880 $6.83 Million
Q1 2022 May 13, 2022	SELL	$10.07 - $11.93 $119,802 - $141,931	-11,897 Reduced 1.98%	589,880 $6.83 Million
Q4 2021 Feb 14, 2022	BUY	$7.95 - $11.24 $84,047 - $118,829	10,572 Added 1.79%	601,777 $6.68 Million
Q3 2021 Nov 15, 2021	BUY	$9.22 - $12.44 $5.45 Million - $7.35 Million	591,205 New	591,205 $5.45 Million

Others Institutions Holding LNDC

# of Institutions

Shares Held

21.6M

Call Options Held

114K

Put Options Held

82.1K

View Full List

About LANDEC CORP \CA\

Ticker LNDC
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,595,600
Description
Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...

More about LNDC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account